Lortalamine

DB09187

small molecule experimental

Deskripsi

Lortalamine (LM-1404) is a selective norepinephrine reuptake inhibitor developed in the 1980s. This drug never made it past clinical trials, likely due to ocular toxicity in animals, but has been used in positron emission tomography studies to label norepinephrine transporters.

Struktur Molekul 2D

Berat 292.76
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

677 Data
Buprenorphine Lortalamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Lortalamine.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Lortalamine.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Lortalamine.
Hydrocodone Lortalamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Lortalamine.
Magnesium sulfate The therapeutic efficacy of Lortalamine can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Lortalamine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Lortalamine may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Lortalamine.
Mirtazapine Lortalamine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Lortalamine.
Orphenadrine Lortalamine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Lortalamine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Lortalamine.
Pramipexole Lortalamine may increase the sedative activities of Pramipexole.
Ropinirole Lortalamine may increase the sedative activities of Ropinirole.
Rotigotine Lortalamine may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Lortalamine.
Sodium oxybate Lortalamine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Suvorexant Lortalamine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Lortalamine.
Thalidomide Lortalamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Lortalamine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Lortalamine.
Dicoumarol The risk or severity of adverse effects can be increased when Lortalamine is combined with Dicoumarol.
Phenindione The risk or severity of adverse effects can be increased when Lortalamine is combined with Phenindione.
Warfarin The risk or severity of adverse effects can be increased when Lortalamine is combined with Warfarin.
Phenprocoumon The risk or severity of adverse effects can be increased when Lortalamine is combined with Phenprocoumon.
Acenocoumarol The risk or severity of adverse effects can be increased when Lortalamine is combined with Acenocoumarol.
4-hydroxycoumarin The risk or severity of adverse effects can be increased when Lortalamine is combined with 4-hydroxycoumarin.
Coumarin The risk or severity of adverse effects can be increased when Lortalamine is combined with Coumarin.
(R)-warfarin The risk or severity of adverse effects can be increased when Lortalamine is combined with (R)-warfarin.
Ethyl biscoumacetate The risk or severity of adverse effects can be increased when Lortalamine is combined with Ethyl biscoumacetate.
Fluindione The risk or severity of adverse effects can be increased when Lortalamine is combined with Fluindione.
Clorindione The risk or severity of adverse effects can be increased when Lortalamine is combined with Clorindione.
Diphenadione The risk or severity of adverse effects can be increased when Lortalamine is combined with Diphenadione.
Tioclomarol The risk or severity of adverse effects can be increased when Lortalamine is combined with Tioclomarol.
(S)-Warfarin The risk or severity of adverse effects can be increased when Lortalamine is combined with (S)-Warfarin.
Ethanol Lortalamine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Azelastine Lortalamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Lortalamine.
Fluvoxamine The risk or severity of adverse effects can be increased when Lortalamine is combined with Fluvoxamine.
Citalopram The risk or severity of adverse effects can be increased when Lortalamine is combined with Citalopram.
Duloxetine The risk or severity of adverse effects can be increased when Lortalamine is combined with Duloxetine.
Trazodone The risk or severity of adverse effects can be increased when Lortalamine is combined with Trazodone.
Paroxetine The risk or severity of adverse effects can be increased when Lortalamine is combined with Paroxetine.
Sertraline The risk or severity of adverse effects can be increased when Lortalamine is combined with Sertraline.
Sibutramine The risk or severity of adverse effects can be increased when Lortalamine is combined with Sibutramine.
Nefazodone The risk or severity of adverse effects can be increased when Lortalamine is combined with Nefazodone.
Escitalopram The risk or severity of adverse effects can be increased when Lortalamine is combined with Escitalopram.
Zimelidine The risk or severity of adverse effects can be increased when Lortalamine is combined with Zimelidine.
Dapoxetine The risk or severity of adverse effects can be increased when Lortalamine is combined with Dapoxetine.
Milnacipran The risk or severity of adverse effects can be increased when Lortalamine is combined with Milnacipran.
Desvenlafaxine The risk or severity of adverse effects can be increased when Lortalamine is combined with Desvenlafaxine.
Seproxetine The risk or severity of adverse effects can be increased when Lortalamine is combined with Seproxetine.
Indalpine The risk or severity of adverse effects can be increased when Lortalamine is combined with Indalpine.
Ritanserin The risk or severity of adverse effects can be increased when Lortalamine is combined with Ritanserin.
Alaproclate The risk or severity of adverse effects can be increased when Lortalamine is combined with Alaproclate.
Iobenguane Lortalamine can cause a decrease in the absorption of Iobenguane resulting in a reduced serum concentration and potentially a decrease in efficacy.
Zopiclone The risk or severity of adverse effects can be increased when Lortalamine is combined with Zopiclone.
Botulinum toxin type B The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Lortalamine.
Botulinum toxin type A The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Lortalamine.
Tryptophan The risk or severity of CNS depression can be increased when Tryptophan is combined with Lortalamine.
Baclofen Baclofen may increase the central nervous system depressant (CNS depressant) activities of Lortalamine.
Lorazepam The risk or severity of CNS depression can be increased when Lorazepam is combined with Lortalamine.
Ethchlorvynol The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Lortalamine.
Succinylcholine The risk or severity of CNS depression can be increased when Succinylcholine is combined with Lortalamine.
Reserpine The risk or severity of CNS depression can be increased when Reserpine is combined with Lortalamine.
Eletriptan The risk or severity of CNS depression can be increased when Eletriptan is combined with Lortalamine.
Enflurane The risk or severity of CNS depression can be increased when Enflurane is combined with Lortalamine.
Temazepam The risk or severity of CNS depression can be increased when Temazepam is combined with Lortalamine.
Reboxetine The risk or severity of CNS depression can be increased when Reboxetine is combined with Lortalamine.
Butabarbital The risk or severity of CNS depression can be increased when Butabarbital is combined with Lortalamine.
Butalbital The risk or severity of CNS depression can be increased when Butalbital is combined with Lortalamine.
Methysergide The risk or severity of CNS depression can be increased when Methysergide is combined with Lortalamine.
Cabergoline The risk or severity of CNS depression can be increased when Cabergoline is combined with Lortalamine.
Phenytoin The risk or severity of CNS depression can be increased when Phenytoin is combined with Lortalamine.
Topiramate The risk or severity of CNS depression can be increased when Topiramate is combined with Lortalamine.
Clemastine The risk or severity of CNS depression can be increased when Clemastine is combined with Lortalamine.
Venlafaxine The risk or severity of CNS depression can be increased when Venlafaxine is combined with Lortalamine.
Etomidate The risk or severity of CNS depression can be increased when Etomidate is combined with Lortalamine.
Morphine The risk or severity of CNS depression can be increased when Morphine is combined with Lortalamine.
Talbutal The risk or severity of CNS depression can be increased when Talbutal is combined with Lortalamine.
Pentobarbital The risk or severity of CNS depression can be increased when Pentobarbital is combined with Lortalamine.
Valproic acid The risk or severity of CNS depression can be increased when Valproic acid is combined with Lortalamine.
Zolmitriptan The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Lortalamine.
Codeine The risk or severity of CNS depression can be increased when Codeine is combined with Lortalamine.
Dihydroergotamine The risk or severity of CNS depression can be increased when Dihydroergotamine is combined with Lortalamine.
Amitriptyline The risk or severity of CNS depression can be increased when Amitriptyline is combined with Lortalamine.
Tolcapone The risk or severity of CNS depression can be increased when Tolcapone is combined with Lortalamine.
Hydromorphone The risk or severity of CNS depression can be increased when Hydromorphone is combined with Lortalamine.
Olanzapine The risk or severity of CNS depression can be increased when Olanzapine is combined with Lortalamine.
Cetirizine The risk or severity of CNS depression can be increased when Cetirizine is combined with Lortalamine.
Protriptyline The risk or severity of CNS depression can be increased when Protriptyline is combined with Lortalamine.
Trimethadione The risk or severity of CNS depression can be increased when Trimethadione is combined with Lortalamine.
Clobazam The risk or severity of sedation, somnolence, and CNS depression can be increased when Clobazam is combined with Lortalamine.
Chlorzoxazone The risk or severity of CNS depression can be increased when Chlorzoxazone is combined with Lortalamine.
Clozapine The risk or severity of CNS depression can be increased when Clozapine is combined with Lortalamine.
Meprobamate The risk or severity of CNS depression can be increased when Meprobamate is combined with Lortalamine.

Referensi & Sumber

Artikel (PubMed)
  • PMID: 6113932
    Belleville M, Grand M, Briet P: Plasma levels, elimination and metabolic fate of 4a-amino-8-chloro-2-methyl-1,2,3,4,4a,10a-hexahydro-10H-benzopyrano3,2-cpyridin -10-ylacetic acid lactam, a new antidepressive agent, in rats and dogs. Drug Metab Dispos. 1981 May-Jun;9(3):233-9.
  • PMID: 4091869
    Depin JC, Betbeder-Matibet A, Bonhomme Y, Muller AJ, Berthelon JJ: Pharmacology of lortalamine, a new potent non-tricyclic antidepressant. Arzneimittelforschung. 1985;35(11):1655-62.
  • PMID: 15914010
    Lin KS, Ding YS: Synthesis and C-11 labeling of three potent norepinephrine transporter selective ligands ((R)-nisoxetine, lortalamine, and oxaprotiline) for comparative PET studies in baboons. Bioorg Med Chem. 2005 Aug 1;13(15):4658-66.
  • PMID: 4085522
    Elsom LF, Biggs SR, Chasseaud LF, Hawkins DR, Pulsford J, Darragh A: Metabolism of the anti-depressant lortalamine. Eur J Drug Metab Pharmacokinet. 1985 Jul-Sep;10(3):209-15.
  • PMID: 2279460
    Mally C, Thiebault JJ: Ocular toxicity in beagle dogs with lortalamine, a non tricyclic antidepressant compound. Drug Chem Toxicol. 1990;13(4):309-23.
  • PMID: 15998285
    Ding YS, Lin KS, Logan J, Benveniste H, Carter P: Comparative evaluation of positron emission tomography radiotracers for imaging the norepinephrine transporter: (S,S) and (R,R) enantiomers of reboxetine analogs (11Cmethylreboxetine, 3-Cl-11Cmethylreboxetine and 18Ffluororeboxetine), (R)-11Cnisoxetine, 11Coxaprotiline and 11Clortalamine. J Neurochem. 2005 Jul;94(2):337-51.
  • PMID: 17073682
    Ding YS, Lin KS, Logan J: PET imaging of norepinephrine transporters. Curr Pharm Des. 2006;12(30):3831-45.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul